493 related articles for article (PubMed ID: 34368124)
1. Identification of a Novel Immune Landscape Signature for Predicting Prognosis and Response of Endometrial Carcinoma to Immunotherapy and Chemotherapy.
Liu J; Wang Y; Mei J; Nie S; Zhang Y
Front Cell Dev Biol; 2021; 9():671736. PubMed ID: 34368124
[TBL] [Abstract][Full Text] [Related]
2. Development and Clinical Validation of Novel 8-Gene Prognostic Signature Associated With the Proportion of Regulatory T Cells by Weighted Gene Co-Expression Network Analysis in Uterine Corpus Endometrial Carcinoma.
Liu J; Geng R; Yang S; Shao F; Zhong Z; Yang M; Ni S; Cai L; Bai J
Front Immunol; 2021; 12():788431. PubMed ID: 34970268
[TBL] [Abstract][Full Text] [Related]
3. Development of Personalized Signature Based on the Immune Landscape to Predict the Prognosis of Osteosarcoma and the Response to Immunotherapy and Targeted Therapy.
Feng X; Zhao Z; Zhao Y; Song Z; Ma Y; Wang W
Front Mol Biosci; 2021; 8():783915. PubMed ID: 35127816
[TBL] [Abstract][Full Text] [Related]
4. Identification of an immune gene signature for predicting the prognosis of patients with uterine corpus endometrial carcinoma.
Zhou C; Li C; Yan F; Zheng Y
Cancer Cell Int; 2020 Nov; 20(1):541. PubMed ID: 33292199
[TBL] [Abstract][Full Text] [Related]
5. Identification of methylation-driven genes prognosis signature and immune microenvironment in uterus corpus endometrial cancer.
Liu J; Ji C; Wang Y; Zhang C; Zhu H
Cancer Cell Int; 2021 Jul; 21(1):365. PubMed ID: 34246261
[TBL] [Abstract][Full Text] [Related]
6. FAT2 mutation is associated with better prognosis and responsiveness to immunotherapy in uterine corpus endometrial carcinoma.
Wang Z; Xing L; Huang Y; Han P
Cancer Med; 2023 Feb; 12(3):3797-3811. PubMed ID: 36812126
[TBL] [Abstract][Full Text] [Related]
7. Construction of a novel immune response prediction signature to predict the efficacy of immune checkpoint inhibitors in clear cell renal cell carcinoma patients.
Yao J; Liang Z; Duan L; G Y; Liu J; An G
Heliyon; 2023 Jun; 9(6):e15925. PubMed ID: 37484396
[TBL] [Abstract][Full Text] [Related]
8. Integrated bioinformatics analysis and experimental validation reveals fatty acid metabolism-related prognostic signature and immune responses for uterine corpus endometrial carcinoma.
Guo C; He Y; Chen L; Li Y; Wang Y; Bao Y; Zeng N; Jiang F; Zhou H; Zhang L
Front Oncol; 2022; 12():1030246. PubMed ID: 36439473
[TBL] [Abstract][Full Text] [Related]
9. Construction of N-7 methylguanine-related mRNA prognostic model in uterine corpus endometrial carcinoma based on multi-omics data and immune-related analysis.
Zhao J; Zou J; Jiao W; Lin L; Wang J; Lin Z
Sci Rep; 2022 Nov; 12(1):18813. PubMed ID: 36335189
[TBL] [Abstract][Full Text] [Related]
10. Development and validation of a novel DNA damage repair-related long non-coding RNA signature in predicting prognosis, immunity, and drug sensitivity in uterine corpus endometrial carcinoma.
Wang T; Ji M; Liu W; Sun J
Comput Struct Biotechnol J; 2023; 21():4944-4959. PubMed ID: 37876625
[TBL] [Abstract][Full Text] [Related]
11. Inflammation-Related LncRNAs Signature for Prognosis and Immune Response Evaluation in Uterine Corpus Endometrial Carcinoma.
Gu H; Song J; Chen Y; Wang Y; Tan X; Zhao H
Front Oncol; 2022; 12():923641. PubMed ID: 35719911
[TBL] [Abstract][Full Text] [Related]
12. Protein-based prognostic signature for predicting the survival and immunotherapeutic efficiency of endometrial carcinoma.
Lai J; Xu T; Yang H
BMC Cancer; 2022 Mar; 22(1):325. PubMed ID: 35337291
[TBL] [Abstract][Full Text] [Related]
13. Positive Correlation Between LTA Expression and Overall Immune Activity Suggests an Increased Probability of Survival in Uterine Corpus Endometrial Carcinoma.
Shi M; Luo F; Shao T; Zhang H; Yang T; Wei Y; Chen R; Guo R
Front Cell Dev Biol; 2021; 9():793793. PubMed ID: 35155447
[TBL] [Abstract][Full Text] [Related]
14. Identification and Validation of an Immune-related Prognostic Signature for Hepatocellular Carcinoma.
Xia X; Tang P; Liu H; Li Y
J Clin Transl Hepatol; 2021 Dec; 9(6):798-808. PubMed ID: 34966643
[TBL] [Abstract][Full Text] [Related]
15. Development of an Oxidative Phosphorylation-Related and Immune Microenvironment Prognostic Signature in Uterine Corpus Endometrial Carcinoma.
Liu J; Chen T; Yang M; Zhong Z; Ni S; Yang S; Shao F; Cai L; Bai J; Yu H
Front Cell Dev Biol; 2021; 9():753004. PubMed ID: 34901000
[No Abstract] [Full Text] [Related]
16. Identification of the Prognostic Signature Associated With Tumor Immune Microenvironment of Uterine Corpus Endometrial Carcinoma Based on Ferroptosis-Related Genes.
Liu J; Wang Y; Meng H; Yin Y; Zhu H; Ni T
Front Cell Dev Biol; 2021; 9():735013. PubMed ID: 34692692
[No Abstract] [Full Text] [Related]
17. Construction of the novel immune risk scoring system related to CD8
Zhang G; Yin Z; Fang J; Wu A; Chen G; Cao K
Cancer Cell Int; 2023 Jun; 23(1):124. PubMed ID: 37349706
[TBL] [Abstract][Full Text] [Related]
18. Multiomics profile and prognostic gene signature of m6A regulators in uterine corpus endometrial carcinoma.
Wang Y; Ren F; Song Z; Wang X; Ma X
J Cancer; 2020; 11(21):6390-6401. PubMed ID: 33033522
[TBL] [Abstract][Full Text] [Related]
19. Identification of an integrated kinase-related prognostic gene signature associated with tumor immune microenvironment in human uterine corpus endometrial carcinoma.
Wei S; Zhang J; Shi R; Yu Z; Chen X; Wang H
Front Oncol; 2022; 12():944000. PubMed ID: 36158685
[TBL] [Abstract][Full Text] [Related]
20. Endoplasmic reticulum stress related IncRNA signature predicts the prognosis and immune response evaluation of uterine corpus endometrial carcinoma.
Chen J; Shen L; Yang Y
Front Oncol; 2022; 12():1064223. PubMed ID: 36686816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
